Exergame-based Program Shown to Be Feasible for Parkinson’s Rehab
A cognitive-motor training program featuring a video game platform that promotes exercise is feasible for people with Parkinson’s disease to…
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
A cognitive-motor training program featuring a video game platform that promotes exercise is feasible for people with Parkinson’s disease to…
Treatment with stem cells engineered to produce a signaling protein called VEGF — which drives the growth of blood vessels…
VectorY Therapeutics and Annogen have announced a new agreement to work toward developing vectorized antibody therapies for…
A Phase 2b clinical trial testing the investigational oral therapy mesdopetam, which aims to reduce levodopa-induced dyskinesia (involuntary movements)…
A new metric called the Parkinson’s Disease Social Functioning Scale (PDSFS) can measure social functioning in people with Parkinson’s…
Seal Rock Therapeutics says its novel oral therapy program SRT-055, which aims to treat Parkinson’s disease and other…
A liquid formulation of levodopa/carbidopa (LD/CD) delivered continuously under the skin via a pump, ND0612 is more effective than…
Analyses done by machine learning of data collected in brain imaging, clinical exams, and laboratory tests can be used to predict…
A novel machine learning algorithm was able to accurately classify people with Parkinson’s disease based on their predicted rate…
Mortality rates appear to be lower among people with Parkinson’s disease psychosis (PDP) being treated with Nuplazid (pimavanserin)…
Get regular updates to your inbox.